Jan 24, 2022 10:19am EST Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans
Jan 18, 2022 7:30am EST Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program
Jan 13, 2022 7:30am EST Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients
Jan 10, 2022 7:30am EST Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds
Dec 22, 2021 7:30am EST Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments
Dec 09, 2021 10:41am EST Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
Dec 06, 2021 7:30am EST Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
Nov 16, 2021 7:30am EST Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 10, 2021 7:30am EST Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021